CD47 related compositions and methods for treating immunological diseases and disorders

• US 20080131431A1
• Filed: 05/15/2007
• Published: 06/05/2008
• Est. Priority Date: 05/15/2006
• Status: Abandoned Application

• Current Assignee: Board of Trustees of the Leland Stanford Junior University (Stanford Management Co.)
• Original Assignee: Viral Logic Systems Technology Corporation
• Inventors: Smith, Craig A., Probst, Peter, Kaykas, Ajamete, Wiley, Steven
• Application Number:
  US11/804,992
• Publication Number:
  US 20080131431A1
• Time in Patent Office: Days
• US Class Current: 424/134.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/177 Receptors; Cell surface antigens; Cell surface determinants
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 21/04 for myasthenia gravis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07K 14/70596 : Molecules with a "CD"-designation not provided for elsewhere
• CPC Class Codes: C07K 2319/30 : Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C07K 2319/32 : fusions with soluble part of a cell surface receptor, "decoy receptors"

Abstract

Provide herein are fusion polypeptides that comprise a CD47 extracellular domain or a variant thereof that is fused to a Fc polypeptide. The fusion polypeptides are useful for treating an immunological disease or disorder in a subject according to the methods described herein. The fusion polypeptides are capable of suppressing immunoresponsiveness of an immune cell, inhibiting production of proinflammatory cytokines, including inhibiting immune complex-induced production of cytokines.

Claims

1. A fusion polypeptide comprising an extracellular domain of CD47 fused to a human IgG1 Fc polypeptide, wherein the Fc polypeptide comprises a substitution or a deletion of a cysteine residue in the hinge region, wherein the substituted or deleted cysteine residue is the cysteine residue most proximal to the amino terminus of the hinge region of the Fc portion of a wildtype human IgG1 immunoglobulin, and wherein the Fc polypeptide further comprises a substitution or deletion of an aspartate residue immediately adjacent to the cysteine residue most proximal to the amino terminus of the hinge region of the Fc portion of a wildtype human IgG1 immunoglobulin, wherein the fusion polypeptide alters the immunoresponsiveness of an immune cell.

4. The fusion polypeptide according to claim 1 wherein the fusion polypeptide comprises an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO:

2.

5. The fusion polypeptide according to claim 1 wherein the extracellular domain of human CD47 comprises an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO:

1 wherein the cysteine residues located at positions corresponding to positions 15, 23, and 96 of SEQ ID NO;

1 are retained.

6. The fusion polypeptide according to claim 5 wherein the extracellular domain of human CD47 comprises the amino acid sequence set forth in SEQ ID NO:

1.

7. The fusion polypeptide according to claim 1 wherein the extracellular domain of human CD47 comprises an amino acid sequence at least 95% identical to the sequence set forth in SEQ ID NO:

11 wherein the cysteine residues located at positions corresponding to positions 33, 41, and 114 of SEQ ID NO;

11 are retained.

8. The fusion polypeptide according to claim 1 wherein the extracellular domain of human CD47 comprises the amino acid sequence set forth in SEQ ID NO:

11.

9. The fusion polypeptide according to claim 1 wherein the fusion polypeptide is capable of inhibiting immune complex-induced cytokine production in the immune cell.

10. The fusion polypeptide according to claim 1 wherein production of the cytokine IL-23 is inhibited.

11. The fusion polypeptide according to claim 1 wherein production of at least one cytokine selected from IL-23, IL-12, IL-6, and TNF-α

is inhibited.

12. The fusion polypeptide according to claim 1 wherein the Fc polypeptide comprises at least one amino acid substitution to remove a glycosylation site.

13. The fusion polypeptide according to claim 12 wherein the Fc polypeptide is aglycosylated.

14. The fusion polypeptide according to claim 1 wherein the fusion polypeptide further comprises a polypeptide spacer between the Fc polypeptide and the extracellular domain of CD47.

15. The fusion polypeptide according to claim 14 wherein the polypeptide spacer comprises from 5 to 100 amino acid residues independently selected from glycine, asparagine, serine, threonine, and alanine.

16. The fusion polypeptide according to claim 15 wherein the polypeptide spacer comprises 5 to 20 amino acid residues.

17. The fusion polypeptide according to claim 15 wherein the polypeptide spacer comprises (Gly₄Ser)_n wherein n=1-12.

18. The fusion polypeptide according to claim 1 wherein the human IgG1 Fc polypeptide further comprises substitution of (a) at least one amino acid in the CH2 domain of the Fc polypeptide;

(b) at least two amino acid residues in the CH2 domain of the Fc polypeptide or (c) at least three amino acid residues in the CH2 domain of the Fc polypeptide, such that the capability of the fusion polypeptide to bind to an IgG Fc receptor is reduced.

19. The fusion polypeptide according to claim 1, wherein the fusion polypeptide forms a dimer of two fusion polypeptide monomers, and wherein the dimer comprises a disulfide bond between each of the extracellular CD47 domain moieties of each of the two fusion polypeptide monomers.

20. The fusion polypeptide according to claim 19 wherein the disulfide bond between each of the extracellular domain moieties is formed between a cysteine residue of each extracellular CD47 domain moiety, which cysteine residue of each extracellular CD47 domain moiety is most proximal to the amino terminus.

21. The fusion polypeptide according to claim 20 wherein the CD47 extracellular domain variant retains the capability to bind at least one CD47 ligand selected from SIRP-α

, SIRP-beta-2, thrombospondin-1, α

_vβ

₃ integrin, and α

₂β

₁ integrin.

22. The fusion polypeptide according to claim 20 wherein the fusion polypeptide (a) competitively inhibits binding of at least one CD47 ligand to a CD47 polypeptide expressed on the cell surface of a cell and (b) competitively inhibits binding of a viral CD47-like polypeptide to at least one CD47 ligand.

23. The fusion polypeptide according to claim 22 wherein the at least one CD47 ligand is selected from SIRP-α

, SIRP-beta-2, thrombospondin-1, α

_vβ

₃ integrin, and α

₂β

₁ integrin.

24. The fusion polypeptide according to claim 23 wherein the fusion polypeptide competitively inhibits binding of at least one CD47 ligand to a cellular CD47 polypeptide by binding to the at least one CD47 ligand.

25. The fusion polypeptide according to claim 20 wherein altering immunoresponsiveness of the immune cell comprises at least one of (a) altering cell migration;

(b) inhibiting production of at least one cytokine selected from TNF-α

, IL-12, IL-23, IFN-γ

, GM-CSF, and IL-6;

(c) inhibiting maturation of a dendritic cell;

(d) impairing development of a naï

ve T cell into a Th1 effector cell;

(e) inhibiting activation of the immune cell wherein the immune cell expresses SIRP-α

on the cell surface;

(f) inhibiting production of a chemokine; and

(g) suppressing a proinflammatory response by the immune cell.

26. The fusion polypeptide according to claim 1 wherein the immune cell expresses SIRP-α

on the cell surface, and wherein altering immunoresponsiveness of the immune cell comprises at least one of (a) inhibiting production of at least one cytokine in the immune cell wherein the cytokine is selected from TNF-α

, IL-12, and IL-23;

(b) inhibiting immune complex-induced cytokine production in the immune cell; and

(c) inhibiting production of at least one chemokine, wherein the chemokine is MIP-1α

.

27. The fusion polypeptide according to claim 26 wherein the immune cell is a dendritic cell.

30. A polynucleotide encoding the fusion polypeptide according to claim 1.

31. A recombinant expression construct comprising the polynucleotide of claim 30 operatively linked to an expression control sequence.

32. A host cell transformed or transfected with the recombinant expression construct according to claim 31.

33. The host cell according to claim 32 wherein the host cell is a eukaryotic cell.

34. A composition comprising the fusion polypeptide according to claim 20 and a pharmaceutically suitable carrier.

35. A method of altering an immune response in a subject comprising administering to the subject the composition according to claim 34, thereby altering the immune response in the subject.

36. The method according to claim 35 wherein altering the immune response comprises suppressing the immune response.

37. A method of activating an immune cell comprising contacting the immune cell with the fusion polypeptide according to claim 20, under conditions and a time sufficient to permit the immune cell and the fusion polypeptide to interact, wherein a CD47 ligand is present on the cell surface of the immune cell, thereby activating the immune cell.

38. The method according to claim 37 wherein the CD47 ligand is selected from SIRP-α

, SIRP-beta-2, thrombospondin-1, α

_vβ

₃ integrin, and α

₂β

₁ integrin.

39. The method according to claim 38 wherein the CD47 ligand is SIRP-α

.

40. The method according to claim 37 wherein activating the immune cell comprises inhibiting Fc-mediated cytokine production.

41. The method according to claim 40 wherein inhibiting Fc-mediated chemokine production comprises inhibiting immune complex-induced cytokine production.

42. The method according to claim 37 wherein activating the immune cell comprises inhibiting Fc-mediated chemokine production.

43. The method according to claim 37 wherein the immune cell is a dendritic cell, a monocyte, a granulocyte, or a bone marrow stem cell.

44. A method of inhibiting immune complex-induced cytokine production in an immune cell comprising contacting an immune cell with the fusion polypeptide according to claim 20 under conditions and for a time sufficient to inhibit immune complex-induced cytokine production in the immune cell.

45. The method according to claim 36 wherein the immune cell expresses a CD47 ligand on the cell surface.

46. The method according to claim 45 wherein the CD47 ligand is selected from SIRP-α

, SIRP-beta-2, thrombospondin-1, α

_vβ

₃ integrin, and α

₂β

₁ integrin.

47. The method according to claim 44 wherein the immune cell is a dendritic cell, a monocyte, a granulocyte, or a bone marrow stem cell.

48. The method according to claim 44 wherein the immune cell is a dendritic cell and the CD47 ligand is SIRP-α

.

49. The method according to claim 44 wherein production of at least one cytokine selected from IL-23, IL-12, IL-6, and TNF-α

is inhibited.

50. The method according to claim 44 wherein the fusion polypeptide inhibits binding of the immune complex to the immune cell.

51. A method of treating an immunological disease or disorder in a subject who has or who is at risk of developing the immunological disease or disorder, said method comprising administering to the subject the composition according to claim 34.

57. A method of manufacture for producing the fusion polypeptide according to claim 20.

2-3. -3. (canceled)

28-29. -29. (canceled)

52-54. -54. (canceled)

58. An isolated antibody, or antigen-binding fragment thereof, (a) that specifically binds to CD47 and (b) that competitively inhibits binding of a CD47 ligand (i) to CD47 and (ii) to a viral CD47-like polypeptide.

59. The antibody, or antigen-binding fragment thereof, according to claim 58 wherein the viral CD47-like polypeptide is a poxvirus CD47-like polypeptide.

62. The antibody, or antigen-binding fragment thereof, according to claim 58 wherein the antibody, or antigen-binding fragment thereof, inhibits Fc-mediated cytokine production or chemokine production by an immune cell.

63. The antibody, or antigen-binding fragment thereof, according to claim 62, wherein inhibiting Fc-mediated cytokine production or chemokine production comprises inhibiting immune complex-induced cytokine production or chemokine production by an immune cell.

71. A host cell that expresses the antibody of claim 58.

72. The host cell of claim 71 that is a hybridoma cell.

81. A composition comprising the antibody, or antigen-binding fragment thereof, according to claim 58 and a pharmaceutically suitable carrier.

87. A method of altering an immune response in a subject comprising administering to the subject the composition according to claim 81, thereby altering the immune response of the subject.

91. A method for treating an immunological disease or disorder in a subject comprising administering to the subject the composition according to claim 81.

127. A method of manufacture for producing the antibody, or antigen-binding fragment thereof, according to claim 58.

60-61. -61. (canceled)

64-70. -70. (canceled)

73-75. -75. (canceled)

76. An agent that specifically binds to CD47 and that inhibits binding of a viral CD47-like polypeptide to at least one CD47 ligand.

77-80. -80. (canceled)

82. (canceled)

89. A method of altering an immune response in a subject comprising administering to the subject the composition according to claim 82, thereby altering the immune response of the subject.

83. A method for identifying an agent that alters immunoresponsiveness of an immune cell comprising:

(a) contacting (i) a candidate agent;

(ii) a viral CD47-like polypeptide; and

(iii) a CD47 ligand, under conditions and for a time sufficient to permit interaction between the CD47 ligand and the viral CD47-like polypeptide;

(b) determining a level of binding of the viral CD47-like polypeptide to the CD47 ligand in the presence of the candidate agent and comparing a level of binding of the viral CD47-like polypeptide to the CD47 ligand in the absence of the candidate agent, wherein a decrease in the level of binding of the viral CD47-like polypeptide to the CD47 ligand in the presence of the candidate agent indicates that the candidate agent inhibits binding of the viral CD47-like polypeptide to the CD47 ligand;

(c) contacting (i) the candidate agent;

(ii) a CD47 ligand; and

(iii) an immune cell that expresses CD47, under conditions and for a time sufficient to permit interaction between a CD47 ligand and CD47; and

(d) determining a level of binding of the CD47 ligand to the immune cell in the presence of the candidate agent and comparing a level of binding of the CD47 ligand to the immune cell in the absence of the candidate agent, wherein a decrease in the level of binding of the CD47 ligand to the immune cell in the presence of the candidate agent indicates that the candidate agent alters immunoresponsiveness of the immune cell.

84-86. -86. (canceled)

88. (canceled)

90. (canceled)

92-94. -94. (canceled)

95. A method for treating an immunological disease or disorder in a subject comprising administering to the subject a composition that comprises (a) a pharmaceutically suitable carrier;

and either (i) an agent that specifically binds to CD47 and that impairs binding of a viral CD47-like polypeptide to a CD47 ligand or (ii) an agent that specifically binds to a CD47 ligand and specifically impairs binding of a viral CD47-like polypeptide to the CD47 ligand.

96-99. -99. (canceled)

100. A method of treating a disease or disorder associated with alteration of at least one of cell migration, cell proliferation, and cell differentiation in a subject, wherein the method comprises administering to the subject a pharmaceutically suitable carrier and either (a) an agent that specifically binds to CD47 and that impairs binding of a viral CD47-like polypeptide to a CD47 ligand or (b) an agent that specifically binds to a CD47 ligand and specifically impairs binding of a viral CD47-like polypeptide to the CD47 ligand.

101. The method according to claim 100 wherein the viral CD47-like polypeptide is a poxvirus CD47-like polypeptide.

102-110. -110. (canceled)

111. A method of activating an immune cell comprising contacting the immune cell with either (a) an agent that specifically binds to CD47 and that impairs binding of a viral CD47-like polypeptide to a CD47 ligand, or (b) an agent that specifically binds to a CD47 ligand and that impairs binding of a viral CD47-like polypeptide to a CD47 ligand under conditions and a time sufficient to permit the immune cell and the agent to interact, wherein the CD47 ligand is present on the cell surface of the immune cell, thereby activating the immune cell.

112-119. -119. (canceled)

120. A method of manufacture for producing an agent that suppresses immunoresponsiveness of an immune cell, comprising:

(a) identifying an agent that alters immunoresponsiveness of an immune cell, wherein the step of identifying comprises;

(I) contacting (i) a candidate agent;

(ii) a viral CD47-like polypeptide; and

(iii) a CD47 ligand, under conditions and for a time sufficient to permit interaction between the CD47 ligand and the viral CD47-like polypeptide; and

(II) determining a level of binding of the viral CD47-like polypeptide to the CD47 ligand in the presence of the candidate agent and comparing a level of binding of the viral CD47-like polypeptide to the CD47 ligand in the absence of the candidate agent, wherein a decrease in the level of binding of the viral CD47-like polypeptide to the CD47 ligand in the presence of the candidate agent indicates that the candidate agent inhibits binding of the viral CD47-like polypeptide to the CD47 ligand;

(III) contacting (i) the candidate agent;

(ii) a CD47 ligand; and

(2) an immune cell that expresses CD47, under conditions and for a time sufficient to permit interaction between the CD47 ligand and CD47; and

(IV) determining a level of binding of the CD47 ligand to the immune cell in the presence of the candidate agent and comparing a level of binding of the CD47 ligand to the immune cell in the absence of the candidate agent, wherein a decrease in the level of binding of the CD47 ligand to the immune cell in the presence of the candidate agent indicates that the candidate agent alters immunoresponsiveness of the immune cell; and

(b) producing the agent identified in step (a).

121-126. -126. (canceled)

128. A fusion polypeptide comprising an extracellular domain of a viral CD47 polypeptide fused to an Fc polypeptide.

129-131. -131. (canceled)